Thomas Boesen
Directeur des opérations chez SYNACT PHARMA AB
Profil
Thomas Boesen is the founder of TXP Pharma GmbH.
He is currently the Chief Operating Officer at SynAct Pharma AB.
Previously, he worked as the Director of Drug Discovery at EpiTherapeutics ApS, Principal at Lica Pharmaceuticals A, and Vice President of Discovery at Action Pharma A.
Boesen has a graduate degree from The University of Edinburgh, graduate and doctorate degrees from the University of Copenhagen, and a graduate degree from Roskilde University.
Postes actifs de Thomas Boesen
| Sociétés | Poste | Début |
|---|---|---|
| SYNACT PHARMA AB | Directeur des opérations | 26/01/2021 |
Anciens postes connus de Thomas Boesen
| Sociétés | Poste | Fin |
|---|---|---|
| TXP Pharma GmbH | Fondateur | - |
Lica Pharmaceuticals A/S
 Lica Pharmaceuticals A/S Miscellaneous Commercial ServicesCommercial Services Lica Pharmaceuticals A/S provides biopharmaceutical research and development services. The firm's drugs are used for the treatment of bacterial, parasitic diseases, malaria and leishmaniasis. The company was founded by Arsalan Kharazmi in April 2000 and is headquartered in Copenhagen, Denmark. | Corporate Officer/Principal | - |
EpiTherapeutics ApS
 EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Corporate Officer/Principal | - |
Action Pharma A/S
 Action Pharma A/S BiotechnologyHealth Technology Action Pharma A/S is an R&D-focused biotech company located in the Nordic Medicon Valley area in Copenhagen, Denmark. Action Pharma was founded in 2000 and has a pipeline of 4 drug candidates in different stages of development, plus additional compounds in discovery and early preclinical development. Action Pharma pursues the discovery and development of new drugs and treatment concepts to treat cardiovascular diseases, inflammatory diseases and metabolic diseases, such as type-II diabetes and obesity. Its drug candidates are modified endogenous peptides with improved efficacy and small chemical entities targeted the melanocortin receptors. In disease models, its drug candidates have shown strong effects in treating and preventing inflammation and organ damage in conditions such as post-surgical organ dysfunction and acute myocardial infarction. A major focus for Action Pharma is treatment candidates for type-II diabetes, obesity and metabolic syndrome. Moreover, several drug candidates have shown effects in treating inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and dermatitis. | Corporate Officer/Principal | - |
Formation de Thomas Boesen
| The University of Edinburgh | Graduate Degree |
| University of Copenhagen | Doctorate Degree |
| Roskilde University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SYNACT PHARMA AB | Health Technology |
| Entreprise privées | 4 |
|---|---|
Lica Pharmaceuticals A/S
Lica Pharmaceuticals A/S Miscellaneous Commercial ServicesCommercial Services Lica Pharmaceuticals A/S provides biopharmaceutical research and development services. The firm's drugs are used for the treatment of bacterial, parasitic diseases, malaria and leishmaniasis. The company was founded by Arsalan Kharazmi in April 2000 and is headquartered in Copenhagen, Denmark. | Commercial Services |
Action Pharma A/S
Action Pharma A/S BiotechnologyHealth Technology Action Pharma A/S is an R&D-focused biotech company located in the Nordic Medicon Valley area in Copenhagen, Denmark. Action Pharma was founded in 2000 and has a pipeline of 4 drug candidates in different stages of development, plus additional compounds in discovery and early preclinical development. Action Pharma pursues the discovery and development of new drugs and treatment concepts to treat cardiovascular diseases, inflammatory diseases and metabolic diseases, such as type-II diabetes and obesity. Its drug candidates are modified endogenous peptides with improved efficacy and small chemical entities targeted the melanocortin receptors. In disease models, its drug candidates have shown strong effects in treating and preventing inflammation and organ damage in conditions such as post-surgical organ dysfunction and acute myocardial infarction. A major focus for Action Pharma is treatment candidates for type-II diabetes, obesity and metabolic syndrome. Moreover, several drug candidates have shown effects in treating inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and dermatitis. | Health Technology |
EpiTherapeutics ApS
EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Health Technology |
| TXP Pharma GmbH |
